Abstract
Thiazolidinediones are used to treat type 2 diabetes. Their use has been associated with peripheral edema and congestive heart failure-outcomes that may have a genetic etiology. We genotyped 4,197 participants of the multiethnic DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial with a 50k single nucleotide polymorphisms (SNP) array, which captures ∼2000 cardiovascular, inflammatory, and metabolic genes. We tested 32,088 SNPs for an association with edema among Europeans who received rosiglitazone (n = 965). One SNP, rs6123045, in NFATC2 was significantly associated with edema (odds ratio 1.89 [95% CI 1.47-2.42]; P = 5.32 × 10(-7), corrected P = 0.017). Homozygous individuals had the highest edema rate (hazard ratio 2.89, P = 4.22 × 10(-4)) when compared with individuals homozygous for the protective allele, with heterozygous individuals having an intermediate risk. The interaction between the SNP and rosiglitazone for edema was significant (P = 7.68 × 10(-3)). Six SNPs in NFATC2 were significant in both Europeans and Latin Americans (P < 0.05). Genetic variation at the NFATC2 locus contributes to edema among individuals who receive rosiglitazone.
References
May 6, 1998·Cell·J D MolkentinE N Olson
Nov 25, 2000·Diabetes Care·S AronoffR L Schneider
May 3, 2001·The New England Journal of Medicine·J TuomilehtoUNKNOWN Finnish Diabetes Prevention Study Group
May 2, 2002·Cell·Gerald R Crabtree, Eric N Olson
Dec 3, 2002·The American Journal of Medicine·Shaun Cho, J Edwin Atwood
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Jul 11, 2006·The Journal of Clinical Endocrinology and Metabolism·Lars HansenRickey R Reinhardt
Sep 26, 2006·Lancet·H C GersteinR R Holman
Oct 24, 2006·Diabetes Research and Clinical Practice·Helen D BerlieLinda A Jaber
Oct 2, 2007·Lancet·Rodrigo M LagoRichard W Nesto
Nov 16, 2007·Pharmacogenetics and Genomics·Colin SpraggsMichael Mosteller
May 15, 2008·The Journal of Biological Chemistry·Meriem BourajjajLeon J De Windt
Jul 5, 2008·Molecular and Cellular Biochemistry·Yingxia BaoPeiqing Liu
Sep 17, 2008·Pharmacogenetics and Genomics·William J GeeseKoustubh Ranade
Nov 11, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Gualberto RuañoSteven Hanks
Citations
Jan 20, 2011·Human Genetics·Lei SunShelley B Bull
Jul 5, 2012·Translational Psychiatry·D E AdkinsE J C G van den Oord
Sep 22, 2011·Pharmacogenetics and Genomics·Tien-Jyun ChangLee-Ming Chuang
Apr 8, 2010·Diabetologia·L de KoningUNKNOWN EpiDREAM Investigators
Feb 9, 2012·Gene·Andrea Brancaccio
May 20, 2015·The Tohoku Journal of Experimental Medicine·Ning JiangXiangdong Gao
Mar 24, 2016·BMC Bioinformatics·Ruiquan GeFengfeng Zhou
Apr 12, 2016·Nature Reviews. Endocrinology·Kaixin ZhouEwan R Pearson
May 20, 2015·Blood·Christian A FernandezMary V Relling
Mar 24, 2012·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Sunil K KotaKirtikumar D Modi
Dec 19, 2014·Pharmacogenomics·David Della-MorteDavide Lauro
May 18, 2016·Current Heart Failure Reports·Ersilia M DeFilippis, Michael M Givertz
Oct 17, 2015·Journal of the American Society of Nephrology : JASN·Xiaoli ZhouZhongjie Sun
Dec 31, 2014·PloS One·Marie DenisMichelle A Williams
Sep 7, 2016·Pharmacology & Therapeutics·Ilia GoltsmanZaid Abassi
Dec 14, 2017·Phytotherapy Research : PTR·Yingying GaoYi Feng
Feb 21, 2018·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Michelle ThundersPeter Stockwell
Jun 28, 2017·Pharmacotherapy·Nina Elk, Otito F Iwuchukwu
Mar 1, 2017·Pharmacogenomics·Qinxia XuMingkang Zhong
Aug 24, 2013·Oncology Reports·Jun ZhouZehua Wang
Jan 10, 2019·BMC Evolutionary Biology·Langyu Gu, Canwei Xia
Jul 2, 2021·Frontiers in Genetics·Assefa M BayeAdem Y Dawed
Jul 10, 2021·Frontiers in Genetics·Aamir RainaRais A Ganai